ECOR
electroCore·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ECOR
Electrocore, Inc.
A commercial stage bioelectronic medicine company that develops therapeutics for serious conditions in neurology and rheumatology
Healthcare Equipment and Supplies
--
06/22/2018
NASDAQ Stock Exchange
73
12-31
Common stock
200 Forge Way, Suite 205, Rockaway, NJ , 07866
--
ElectroCore, Inc., was incorporated in Delaware in September 2005. The Company is a commercial-stage bioelectronic medicine and general health company dedicated to improving health and quality of life through a proprietary non-invasive vagus nerve stimulation (" nVNS ") technology platform.
Earnings Call
Company Financials
EPS
ECOR has released its 2025 Q3 earnings. EPS was reported at -0.4, versus the expected -0.4, meeting expectations. The chart below visualizes how ECOR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ECOR has released its 2025 Q3 earnings report, with revenue of 8.69M, reflecting a YoY change of 32.58%, and net profit of -3.40M, showing a YoY change of -36.36%. The Sankey diagram below clearly presents ECOR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available


